Publications

1. PMID: 32961131

Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.

Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, Scholler J, Montine TJ, Bhoj VG, Reddy R, Mohan S, Maillard I, Kriegstein AR, June CH, Chang HY, Posey AD Jr, Satpathy AT.Cell. 2020 Oct 1;183(1):126-142.e17. doi: 10.1016/j.cell.2020.08.022. Epub 2020 Sep 21.PMID: 32961131

Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source.

Zhang Z, Schuster SJ, Lacey SF, Milone MC, Monos D, Bhoj VG.Blood Adv. 2020 Sep 22;4(18):4292-4295. doi: 10.1182/bloodadvances.2020002435.PMID: 32915973 Free PMC article.

3. PMID: 31738832

CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.

Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, Paessler M, June CH, Luning Prak ET, Bhoj VG, Grupp SA, Maude SL, Rheingold SR.Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692.PMID: 31738832 Free PMC article.

4. PMID: 30275568

Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, Klichinsky M, Shestova O, Patel PR, Kulikovskaya I, Nazimuddin F, Bhoj VG, Orlando EJ, Fry TJ, Bitter H, Maude SL, Levine BL, Nobles CL, Bushman FD, Young RM, Scholler J, Gill SI, June CH, Grupp SA, Lacey SF, Melenhorst JJ.Nat Med. 2018 Oct;24(10):1499-1503. doi: 10.1038/s41591-018-0201-9. Epub 2018 Oct 1.PMID: 30275568 Free PMC article.

5. PMID: 29552577

The Pharmacology of T Cell Therapies.

Milone MC, Bhoj VG.Mol Ther Methods Clin Dev. 2018 Jan 31;8:210-221. doi: 10.1016/j.omtm.2018.01.010. eCollection 2018 Mar 16.PMID: 29552577 Free PMC article. Review.

6. PMID: 29226764

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, Brogdon JL, Pruteanu-Malinici I, Bhoj V, Landsburg D, Wasik M, Levine BL, Lacey SF, Melenhorst JJ, Porter DL, June CH.N Engl J Med. 2017 Dec 28;377(26):2545-2554. doi: 10.1056/NEJMoa1708566. Epub 2017 Dec 10.PMID: 29226764 Free PMC article. Clinical Trial.

7. PMID: 27365313

Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease.

Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS.Science. 2016 Jul 8;353(6295):179-84. doi: 10.1126/science.aaf6756. Epub 2016 Jun 30.PMID: 27365313 Free PMC article.

8. PMID: 27232514

Novel gene and cellular therapy approaches for treating HIV.

Bhoj VG, Thibodeaux SR, Levine BL.Discov Med. 2016 Apr;21(116):283-92.PMID: 27232514 Review.

9. PMID: 27166358

Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

Bhoj VG, Arhontoulis D, Wertheim G, Capobianchi J, Callahan CA, Ellebrecht CT, Obstfeld AE, Lacey SF, Melenhorst JJ, Nazimuddin F, Hwang WT, Maude SL, Wasik MA, Bagg A, Schuster S, Feldman MD, Porter DL, Grupp SA, June CH, Milone MC.Blood. 2016 Jul 21;128(3):360-70. doi: 10.1182/blood-2016-01-694356. Epub 2016 May PMID: 27166358 Free PMC article. Clinical Trial.

10.PMID: 26575088

The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network.

Metjian A, Tanhehco YC, Aqui N, Bhoj VG, Jamensky L, Marques MB, Onwuemene O, Pham HP, Arepally GM.J Clin Apher. 2016 Oct;31(5):448-53. doi: 10.1002/jca.21437. Epub 2015 Nov 17.PMID: 26575088